Abstract
Tuberculosis is a major cause of death in mankind and BCG vaccine protects against childhood but not adult tuberculosis. BCG avoids lysosomal fusion in macrophages decreasing peptides required for activating CD4 T cells and Th1 immunity while suppressing the expression of MHC-II by antigen presenting cells (APCs). An in vitro model of antigen presentation showed that ligands for TLR-9, 7, 4 and 1/2 increased the ability of APCs to present antigen-85B of BCG to CD4 T cells, which correlated with an increase in MHC-II expression. TLR-activation led to a down-regulation of MARCH1 ubiquitin ligase which prevents the degradation of MHC-II and decreased IL-10 also contributed to an increase in MHC-II. TLR-activation induced up-regulation of MHC-II was inhibited by the blockade of IRAK, NF-kB, and MAPKs. TLR-7 and TLR-9 ligands had the most effective adjuvant like effect on MHC-II of APCs which allowed BCG vaccine mediated activation of CD4 T cells.
Original language | English (US) |
---|---|
Pages (from-to) | 53-61 |
Number of pages | 9 |
Journal | Cellular Immunology |
Volume | 287 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2014 |
Keywords
- Antigen processing
- BCG vaccine
- CD80
- CD86
- Dendritic cells
- IL-10
- MARCH1 ubiquitin ligase
- MHC-II
- Macrophage
- Toll-like receptor (TLR)
ASJC Scopus subject areas
- Immunology